The American Journal of Medicine
Volume 119, Issue 4, Supplement 1 , Pages S18-S24 , April 2006

Improving Compliance and Persistence with Bisphosphonate Therapy for Osteoporosis

  • Ronald D. Emkey, MD

      Affiliations

    • Radiant Research, Wyomissing, Pennsylvania, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Ronald D. Emkey, MD, Radiant Research, 1235 Penn Avenue, Suite 200, Wyomissing, Pennsylvania 19610.
    • ,
  • Mark Ettinger, MD

      Affiliations

    • Radiant Research, Wyomissing, Pennsylvania, USA
    • Regional Osteoporosis Center, Stuart, Florida, USA

  • Image Result

    (A) Unrecognized vertebral fracture in women ≥60 years of age, hospitalized for various reasons (n=132 of 934). (B) Undertreatment of hip fracture for hospitalized patients (N=1,076) from 4 Midwestern

    (A) Unrecognized vertebral fracture in women ≥60 years of age, hospitalized for various reasons (n=132 of 934). (B) Undertreatment of hip fracture for hospitalized patients (N=1,076) from 4 Midwestern hospitals. BP = blood pressure; DXA = dual X-ray absorptiometry. (Adapted from Osteoporos Int1 and Arthritis Rheum.2)

  • Image Result
    Patients on existing bisphosphonate therapy who remained on therapy after 12 months. (Adapted from Arthritis Rheum.24)

    Patients on existing bisphosphonate therapy who remained on therapy after 12 months. (Adapted from Arthritis Rheum.24)

  • Image Result
    Changes in lumbar spine bone mineral density with daily risedronate (5 mg) and 2 formulations of once-weekly risedronate (35 mg and 50 mg). (Adapted from Calcif Tissue Int.28)

    Changes in lumbar spine bone mineral density with daily risedronate (5 mg) and 2 formulations of once-weekly risedronate (35 mg and 50 mg). (Adapted from Calcif Tissue Int.28)

  • Image Result
    Changes in lumbar spine bone mineral density (BMD) with daily ibandronate (2.5 mg) and 3 formulations of once-monthly ibandronate (50/50 mg, 100 mg, and 150 mg). ⁎P <0.001 vs daily regimen. (Adapted f

    Changes in lumbar spine bone mineral density (BMD) with daily ibandronate (2.5 mg) and 3 formulations of once-monthly ibandronate (50/50 mg, 100 mg, and 150 mg). ⁎P <0.001 vs daily regimen. (Adapted from “Once-monthly Oral Ibandronate Dosing Is Highly Efficacious in Postmenopausal Osteoporosis.”31)

PII: S0002-9343(05)01199-X

doi: 10.1016/j.amjmed.2005.12.019

The American Journal of Medicine
Volume 119, Issue 4, Supplement 1 , Pages S18-S24 , April 2006

Article Tools

* Image Usage & Resolution